百濟神州BRUKINSA於初治CLL患者，六年PFS達74%
This data provides strong evidence for BRUKINSA's long-term efficacy and durability in a significant patient population.
Long-term efficacy data (6-year PFS) for BRUKINSA in treatment-naïve CLL.
百济神州公布了BRUKINSA（泽布替尼）在初治慢性淋巴细胞白血病（CLL）患者中具有里程碑意义的6年无进展生存期（PFS）数据。数据显示，六年的PFS率为74%，进一步巩固了BRUKINSA作为一线治疗的疗效和持久性。这一重要的临床结果凸显了BRUKINSA对CLL患者的长期益处。
This data provides strong evidence for BRUKINSA's long-term efficacy and durability in a significant patient population. For the APAC region, where CLL is a prevalent hematological malignancy, these findings are crucial. They support the use of BRUKINSA as a preferred first-line treatment, potentially improving long-term outcomes and quality of life for numerous patients across Asia.
The long-term data for BRUKINSA in treatment-naïve CLL is highly relevant to APAC, as CLL is a significant cancer burden in the region. Demonstrating sustained efficacy over six years reinforces BRUKINSA's value proposition for healthcare providers and patients, potentially leading to wider adoption and improved patient management strategies across Asian markets.
Where this signal fits in the broader landscape.
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-na-ve-chronic-lymphocytic
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
登录